Systemic mastocytosis - Definition of an internal disease;Die systemische Mastozytose - Standortbestimmung einer internistischen Erkrankung

Medizinische Klinik

Volumn 105, Issue 8, 2010, Pages 544-553

  Homann, Jürgen ^a   Kolck, Ulrich W ^a   Ehnes, Andreas ^a   Frieling, Thomas ^b   Raithel, Martin ^c   Molderings, Gerhard J ^d  

^a Abteilung für Innere Medizin Gemeinschaftskrankenhaus Bonn GGmbH   (Germany)

^b HELIOS KLINIKUM KREFELD   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Diagnostics; Irritable bowel syndrome; Mast cell mediator release syndrome; Systemic mastocytosis; Therapy; Tyrosine kinase Kit

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2B INTERFERON; ALPRAZOLAM; ANTIHISTAMINIC AGENT; ASCORBIC ACID; AZATHIOPRINE; BENZODIAZEPINE; BRADYKININ ANTAGONIST; BUTAPROST; CANNABINOID 1 RECEPTOR AGONIST; CHONDROITIN SULFATE; CYCLOSPORIN; FLUNITRAZEPAM; GLUCOCORTICOID; ICATIBANT; LORAZEPAM; METHOTREXATE; MILTEFOSINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHODIESTERASE IV INHIBITOR; PIOGLITAZONE; PROGESTERONE; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; QUERCETIN; ROLIPRAM; ROSIGLITAZONE; THALIDOMIDE; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; APOPTOSIS; CELL MEMBRANE; CELL PROLIFERATION; CHRONIC DISEASE; DIAGNOSTIC IMAGING; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; INVASIVE PROCEDURE; LABORATORY DIAGNOSIS; MAST CELL; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; SYSTEMIC MASTOCYTOSIS;

ALGORITHMS; APOPTOSIS; ASCORBIC ACID; BIOPSY; BONE MARROW; CODON; COMBINED MODALITY THERAPY; CROMOLYN SODIUM; DELAYED-ACTION PREPARATIONS; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; HISTAMINE H1 ANTAGONISTS; HISTAMINE H2 ANTAGONISTS; HUMANS; KETOTIFEN; MAST CELLS; MASTOCYTOSIS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 77957795043     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-010-1093-8     Document Type: Review

References (37)

1. P. Valent C. Akin L. Escribano 2007 Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria Eur J Clin Invest 37 435 53 1:STN:280:DC%2BD2szisFClsg%3D%3D 10.1111/j.1365-2362.2007.01807.x 17537151 (Pubitemid 46817344)
2. G.J. Molderings U.W. Kolck C. Scheurlen 2007 Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder Scand J Gastroenterol 42 1045 53 1:CAS:528:DC%2BD2sXpt1KisLY%3D 10.1080/00365520701245744 17710669 (Pubitemid 47301141)
3. O. Hermine O. Lortholary P.S. Leventhal 2008 Case-control cohort study of patients' perceptions of disability in mastocytosis PLoS ONE 3 e2266 10.1371/journal.pone.0002266 18509466
4. S.H. He 2004 Key role of mast cells and their major secretory products in inflammatory bowel disease World J Gastroenterol 10 309 18 1:CAS:528: DC%2BD2cXitVyktL4%3D 14760748
5. H. Rosen E.J. Goetzl 2005 Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network Nat Rev Immunol 5 560 70 1:CAS:528: DC%2BD2MXlsl2itr4%3D 10.1038/nri1650 15999095 (Pubitemid 40961333)
6. J.A. Boyce 2007 Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation Immunol Rev 217 168 85 1:CAS:528:DC%2BD2sXnt1Gmurg%3D 10.1111/j.1600-065X.2007.00512.x 17498059 (Pubitemid 46718145)
7. I. Kaneko K. Suzuki K. Matsuo 2009 Cysteinyl leukotrienes enhance the degranulation of bone marrow-derived mast cells through the autocrine mechanism Tohoku J Exp Med 217 185 91 1:CAS:528:DC%2BD1MXkvFCru7o%3D 10.1620/tjem.217.185 19282653
8. M. Castells K.F. Austen 2002 Mastocytosis: mediator related signs and symptoms Int Arch Allergy Immunol 127 147 52 1:CAS:528:DC%2BD38XitlGmtrk%3D 10.1159/000048188 11919427 (Pubitemid 34264205)
9. F. Rueff S. Dugas-Breit C. Bauer 2006 Mastozytose - klinisches Bild und Diagnostik Dtsch Med Wochenschr 131 1616 21 1:STN:280:DC%2BD28vgt1Kruw%3D%3D 10.1055/s-2006-947809 16823715 (Pubitemid 44174041)
10. G.J. Molderings M. Brüss M. Raithel 2005 Systemische Mastozytose als Grund für chronische gastrointestinale Beschwerden Dtsch Ärztebl 102 A1744 9
11. C. Bodemer O. Hermine F. Palmérini 2010 Pediatric mastocytosis is a clonal disease associated with D(816)V and other activating c-KIT mutations J Invest Dermatol 130 804 15 1:CAS:528:DC%2BC3cXhslSks7s%3D 10.1038/jid.2009.281 19865100
12. J. Santos M. Guilarte C. Alonso 2005 Pathogenesis of irritable bowel syndrome: the mast cell connection Scand J Gastroenterol 40 129 40 10.1080/00365520410009410 15764142 (Pubitemid 40192572)
13. G. Barbara V. Stanghellini R. De Giorgio 2006 Functional gastrointestinal disorders and mast cells: implications for therapy Neurogastroenterol Motil 18 6 17 1:STN:280:DC%2BD2MnotlOgtg%3D%3D 10.1111/j.1365-2982.2005.00685.x 16371078
14. G. Delling H. Ritzel M. Werner 2001 Histologische Charakteristika und Häufigkeit der sekundären Osteoporose bei systemischer Mastozytose Pathologe 22 132 40 1:STN:280:DC%2BD3M3jtVSnuw%3D%3D 10.1007/s002920000439 11321729 (Pubitemid 32224311)
15. C. Akin 2005 Clonality and molecular pathogenesis of mastocytosis Acta Haematol 114 61 9 1:CAS:528:DC%2BD2MXlvVSgtLg%3D 10.1159/000085563 15995326 (Pubitemid 40911573)
16. S.J. Galli J. Kalesnikoff M.A. Grimbaldeston 2005 Mast cells as "tunable" effector and immunoregulatory cells: recent advances Annu Rev Immunol 23 749 86 1:CAS:528:DC%2BD2MXktFOju70%3D 10.1146/annurev.immunol.21. 120601.141025 15771585 (Pubitemid 40563184)
17. J. Lennartsson O. Voytyuk E. Heiss 2005 c-Kit signal transduction and involvement in cancer Cancer Ther 3 5 28
18. C.D. Galderisi C.L. Corless J. Wolford 2006 Simultaneous JAK2 V617F and KIT D816V mutations in systemic mastocytosis Mod Pathol 19 225A 6A 10.1038/modpathol.3800523 (Pubitemid 43117606)
19. J. Gotlib N.C.R. Cross D.G. Gilliland 2006 Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy Best Pract Res Clin Haematol 19 535 69 1:CAS:528:DC%2BD28Xls1aqurk%3D 10.1016/j.beha.2005.07. 013 16781488 (Pubitemid 43869477)
20. L. Escribano C. Akin M. Castells 2006 Current options in the treatment of mast cell mediator-re lated symptoms in mastocytosis Inflamm Allergy Drug Targets 5 61 77 1:CAS:528:DC%2BD28XhtVOgsrw%3D 10.2174/187152806775269303 16613565
21. K. Alfter I. von Kügelgen B. Haenisch 2009 New aspects of liver abnormalities as part of the systemic mast cell activation syndrome Liver Int 29 181 6 1:CAS:528:DC%2BD1MXisV2rtLk%3D 10.1111/j.1478-3231.2008.01839.x 18662284
22. L. Escribano I. Alvarez-Twose L. Sánchez-Muñoz 2009 Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients J Allergy Clin Immunol 124 514 21 10.1016/j.jaci.2009.05.003 19541349
23. K.H. Lim A. Tefferi T.L. Lasho 2009 Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors Blood 113 5727 36 1:CAS:528:DC%2BD1MXnsVSksL8%3D 10.1182/blood-2009-02-205237 19363219
24. A. Uzzaman I. Maric P. Noel 2009 Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology Pediatr Blood Cancer 53 629 34 10.1002/pbc.22125 19526526
25. K. Alfter I. von Kügelgen U.W. Kolck 2007 Zur Diagnose und Therapie der systemischen Mastozytose Med Welt 58 621 31
26. G.J. Molderings U. Kolck C. Scheurlen 2006 Die systemische Mastzellerkrankung mit gastrointestinal betonter Symptomatik - eine Checkliste als Diagnoseinstrument Dtsch Med Wochenschr 131 2095 100 1:STN:280: DC%2BD28rltlKnsQ%3D%3D 10.1055/s-2006-951337 16981082 (Pubitemid 44544026)
27. P. Valent H.P. Horny L. Escribano 2001 Diagnostic criteria and classification of mastocytosis: a consensus proposal Leuk Res 25 603 25 1:STN:280:DC%2BD3M3pslylsg%3D%3D 10.1016/S0145-2126(01)00038-8 11377686 (Pubitemid 32506768)
28. L. Pagano C.G. Valentini M. Caira 2008 Advanced mast cell disease: an Italian hematological multicenter experience Int J Hematol 88 483 8 10.1007/s12185-008-0166-4 19034614
29. P. Bonadonna O. Perbellini G. Passalacqua 2009 Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels J Allergy Clin Immunol 123 680 6 1:CAS:528:DC%2BD1MXjtFKqurg%3D 10.1016/j.jaci.2008.11.018 19135713
30. M.R. Johnson S. Verstovsek J.L. Jorgensen 2009 Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow Mod Pathol 22 50 7 10.1038/modpathol.2008.141 19116630
31. O. Perbellini P. Bonadonna C. Vencenzi 2008 Immunophenotypic characterization of neoplastic mast cell in patients with mastocytosis: comparison between flow and cytometry and bone marrow histology Haematologica 93 Suppl2 S69
32. J.H. Butterfield C.Y. Li 2004 Bone marrow biopsies for the diagnosis of systemic mastocytosis - is one biopsy sufficient? Am J Clin Pathol 121 264 7 10.1309/2EWQKN00PG02JKY0 14983941
33. G.J. Molderings 2010 Mast cell function in physiology and pathophysiology BIOTREND Rev 5 1 9
34. B.J. Vlieg-Boerstra S. van der Heide J.N. Oude Elberink 2005 Mastocytosis and adverse reactions to biogenic amines and histamine-releasing foods: what is the evidence? Neth J Med 63 244 9 1:CAS:528:DC%2BD2MXhtVGnsbfI 16093574
35. K. Meis P. Spitzlei I. von Kügelgen 2009 Investigation on the molecular mechanisms mediating the inhibitory effect of benzodiazepines on mast cells Naunyn Schmiedebergs Arch Pharmacol 379 Suppl1 R43
36. R. Nakamura S. Chakrabarti C. Akin 2006 A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis Bone Marrow Transplant 37 353 8 1:STN:280:DC%2BD28%2FnvVejtw%3D%3D 10.1038/sj.bmt.1705245 16400343 (Pubitemid 43250468)
37. AWMF-Leitlinien-Register Nr.061/018. Allergo J 2004;13:440-2.